1. Home
  2. NMM vs TNDM Comparison

NMM vs TNDM Comparison

Compare NMM & TNDM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Navios Maritime Partners LP

NMM

Navios Maritime Partners LP

N/A

Current Price

$67.90

Market Cap

1.7B

ML Signal

N/A

Logo Tandem Diabetes Care Inc.

TNDM

Tandem Diabetes Care Inc.

N/A

Current Price

$24.48

Market Cap

1.4B

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
NMM
TNDM
Founded
2007
2006
Country
Greece
United States
Employees
N/A
N/A
Industry
Marine Transportation
Medical/Dental Instruments
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.7B
1.4B
IPO Year
2007
2013

Fundamental Metrics

Financial Performance
Metric
NMM
TNDM
Price
$67.90
$24.48
Analyst Decision
Buy
Analyst Count
0
18
Target Price
N/A
$28.33
AVG Volume (30 Days)
178.2K
2.4M
Earning Date
05-06-2026
04-29-2026
Dividend Yield
0.37%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$1,014,736,000.00
Revenue This Year
$5.57
$8.01
Revenue Next Year
$3.66
$12.14
P/E Ratio
$7.24
N/A
Revenue Growth
N/A
7.93
52 Week Low
$28.37
$10.00
52 Week High
$74.21
$29.65

Technical Indicators

Market Signals
Indicator
NMM
TNDM
Relative Strength Index (RSI) 56.95 57.63
Support Level $49.57 $19.66
Resistance Level $74.21 $29.65
Average True Range (ATR) 2.69 1.19
MACD -0.15 0.17
Stochastic Oscillator 74.40 67.79

Price Performance

Historical Comparison
NMM
TNDM

About NMM Navios Maritime Partners LP

Navios Maritime Partners LP is a seaborne shipping company. It owns and operates dry cargo and container vessels with the primary long-term and staggered expiration charters. The firm's fleet consists of Ultra- Handymax, Panamax, Capsize, and Container vessels and categorized in Drybulk and Container vessels. It earns revenue through the chartering of vessels and voyage contracts. Geographically, it generates majority revenue from Asia.

About TNDM Tandem Diabetes Care Inc.

Tandem Diabetes designs, manufactures, and markets durable insulin pumps for individuals with diabetes. The firm first entered this market in 2012 and has since introduced multiple generations of pumps leading to its current t:slim X2 device. The firm recently launched its smaller Mobi pump and continues to work on Tobi (a tubeless version of Mobi), and the Sigi tubeless patch pump. Nearly three-quarters of total revenue is derived from the US, with the remainder primarily from other developed nations. The pumps themselves generate just over half of total sales, and another one-third is from disposable infusion sets that need to be changed over every 2 to 3 days.

Share on Social Networks: